Lilly's rheumatoid arthritis pill rejected by regulators

Eli Lilly said U.S. regulators have rejected its much-anticipated pill for the immune disorder rheumatoid arthritis, the drugmaker's second drug development setback since November.The Food and Drug Administration said in a letter to the company that it needed more information about the drug's